Global Cancer Tyrosine Kinase Inhibitors Market Sales Revenue Clinical Trials Pipeline Report 2020

The global increase in the prevalence of cancer and the increasing recognition of the therapeutic and commercial opportunities offered by new oncology treatments has provided a major incentive for the pharmaceutical industry to pursue the development of new agents for the treatment of cancer. To tackle the ever rising global cancer burden, the cancer treatment is inclining towards the targeted drug therapy due to the numerous drawbacks associated with conventional chemotherapy. Targeted drug therapy includes targeting various signaling pathways associated to the tyrosine kinase receptors. Ample of studies have been performed which confirm their intrinsic involvement of tyrosine related pathways in development of the tumors.

Download Report:

https://www.kuickresearch.com/report-Global-Cancer-Tyrosine-Kinase-Inhibitors-Market-&-Clinical-Pipeline-Outlook-2020.php

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

"Cancer Tyrosine Kinase Inhibitors Market & Clinical Pipeline Outlook 2020" Table of Contents

1. The Journey: Genesis to Present of Tyrosine Kinase Inhibitors

2. Tyrosine Kinase: An Overview

3. Tyrosine Kinases Inhibitors: Promising Tools for Targeted Cancer Therapies

4. Types of Tyrosine Kinase Receptors
4.1 Epidermal Growth Factor Receptor
4.1.1 Types of Epidermal Growth Factor Receptor
4.1.2 Epidermal Growth Factor Receptor & Ligands
4.1.3 Epidermal Growth Factor Receptor & Cancers

4.2 Platelet-Derived Growth Factor Receptor (PDGFR)
4.2.1 Types of Platelet-Derived Growth Factor Receptor
4.2.2 Platelet-Derived Growth Factor Receptor & Ligands
4.2.3 Platelet-Derived Growth Factor Receptor & Cancer

4.3 Insulin-Like Growth Factor 1 Receptor (IGF-1R)
4.3.1 Insulin-Like Growth Factor 1 Receptor & its Ligands
4.3.2 Insulin-Like Growth Factor 1 Receptor & its role in Cancer

5. Signaling Pathway of Receptor Tyrosine Kinase
5.1 PI3K/Akt Pathway
5.2 Ras/Raf/ERK1/2 Pathway
5.3 The JAK/STAT Pathway

6. Advantage of Tyrosine Kinase Inhibitors for Treatment of Cancer

7. BCR-ABL Tyrosine Kinase Inhibitors
7.1 Imatinib
7.2 Nilotinib
7.3 Dasatinib
7.4 Ponatinib
7.5 Bosutinib

8. Epidermal Growth Factor Receptor Kinase Inhibitors Tyrosine
8.1 Gefitinib
8.2 Erlotinib
8. 3 Lapatinib
8.4 Icotinib
8.5 Canertinib
8.6 Afatinib
8.7 Neratinib
8.8 Poziotinib

9. Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors
9.1 Sunitinib
9.2 Sorafenib
9.3 Vandetanib
9.4 Pazopanib
9.5 Axitinib
9.6 Cediranib

10. Applications of Tyrosine Kinase Inhibitor in Cancer Therapy
10.1 Role of Tyrosine Kinase Inhibitors in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
10.2 Mitigation of Chronic Myeloid Leukaemia
10.3 Role of tyrosine Kinase Inhibitors in Combating Colorectal Cancer
10.4 Gastrointestinal Cancer & Tyrosine Kinase Inhibitor
10.5 Tyrosine Kinase Inhibitor in Breast Cancer

11. Global Tyrosine Kinase Inhibitors Market Overview
11.1 Current Market Scenario
11.2 Cancer Tyrosine Kinase Inhibitors Pipeline Overview

12. Global Tyrosine Kinase Inhibitor Market Dynamics
12.1 Favorable Driving Factors
12.1.1 Research & Development
12.1.2 Strong Clinical Pipeline
12.1.3 Increasing Disease Incidences
12.1.4 Unmet Requirement of Completely Curative Agents
12.1.5 Advancement in Manufacturing Capabilities of the Biopharmaceutical Companies

12.2 Challenges Countered by Tyrosine Kinase Inhibitor Market
12.2.1 Strict Regulatory Guidelines for Approval of Prospective Drug
12.2.2 Long Phase of Research & Development
12.2.3 Funding of Clinical Trials
12.2.4 Highly Competitive Market

13. Global Tyrosine Kinase Inhibitor Market Future Prospects

14. Global Cancer Tyrosine Kinase Inhibitors Clinical Pipeline by Company, Indication & Phase
14.1 Unknown
14.2 Research
14.3 Preclinical
14.4 Clinical
14.5 Phase-I
14.6 Phase-I/II
14.7 Phase-II
14.8 Phase-II/III
14.9 Phase-III
14.10 Preregistration
14.11 Registered

15. Marketed Cancer Tyrosine Kinase Inhibitors Clinical Insight by Brand Name, Company & Indication
15.1 Blood Cancer
15.1.1 Ibrutinib (Imbruvica)
15.1.2 Ponatinib (Iclusig)
15.1.3 Dasatinib (Tasigna)
15.1.4 Nilotinib (Tasigna)
15.1.5 Bosutinib (Bosulif)
15.1.6 Radotinib (Supect)

15.2 Breast Cancer
15.2.1 Trastuzumab Subcutaneous (Herceptin SC)
15.2.2 Pertuzumab (Omnitarg & Perjeta)
15.2.3 Lapatinib (Tykerb & Tyverb)
15.2.4 Trastuzumab Biosimilar (CANMAb & Hertraz)
15.2.5 Trastuzumab Biosimilar (Vivitra)

15.3 Gastric Cancer
15.3.1 Apatinib

15.4 Non-small cell lung cancer
15.4.1 Afatinib (Gilotrif, Giotrif & Tomtovok)
15.4.2 Nintedanib (Ofev & Vargatef)
15.4.3 Ceritinib (Zykadia)
15.4.4 Crizotinib (Xalkori)
15.4.5 Icotinib (Conmana)
15.4.6 Gefitinib (Iressa)
15.4.7 Alectinib (Alecensa)

15.5 Renal Cancer
15.5.1 Axitinib (Inlyta)

15.6 Thyroid Cancer
15.6.1 Vandetanib (Caprelsa, Zactima & Zictifa)

15.7 Multiple
15.7.1 Sunitinib (Sutent)
15.7.2 Lenvatinib (Lenvima)
15.7.3 Regorafenib (Stivarga)
15.7.4 Imatinib (Gleevec, Glivec & Ruvise)
15.7.5 Trastuzumab (Herceptin)
15.7.6 Erlotinib (Tarceva)
15.7.7 Ramucirumab (Cyramza)
15.7.8 Cabozantinib (COMETRIQ, Cabometyx & Cometriq)
15.7.9 Nimotuzumab (BIOMAb EGFR, CIMAher, Cimaher, Taixinsheng, TheraCIM,
Theraloc & VECTHIX)
15.7.10 Sorafenib (Nexavar)
15.7.11 Imatinib (Imatib)

16. Discontinued & Suspended Cancer Tyrosine Kinase Inhibitors Clinical Pipeline by Company & Phase
16.1 No Development Reported
16.2 Discontinued
16.3 Suspended

17. Competitive Landscape
17.1 AB Science
17.2 Advenchen Laboratories
17.3 Array BioPharma
17.4 ARIAD Pharmaceuticals
17.5 Astellas Pharma (OSI Pharmaceuticals)
17.6 AstraZeneca
17.7 Bayer HealthCare
17.8 Biocad
17.9 Biocon
17.10 Boehringer Ingelheim
17.11 Bristol-Myers Squibb
17.12 Celera Genomics Group
17.13 Celgene Corporation (Avila Therapeutics)
17.14 Celltrion
17.15 Chugai Pharmaceutical
17.16 Cytopia Research
17.17 Daiichi Sankyo (Ambit Biosciences Corporation)
17.18 Dyax
17.19 Eisai Co Ltd
17.20 Exelixis
17.21 GlaxoSmithKline
17.22 Hanmi Pharmaceutical
17.23 Novartis
17.24 Onyx Pharmaceuticals
17.25 Pfizer
17.26 Plexxikon
17.27 Reliance Life Sciences
17.28 Roche
17.29 Shire
17.30 Synthon
17.31 Wyeth
17.32 Xcovery
17.33 Zydus Cadila

Figure 3-1: Pictorial View of Signaling Pathways Involved on Activation of Tyrosine Kinase Receptor
Figure 4-1: Different Types of Tyrosine Kinase Receptors
Figure 5-1: Various Possible Signaling Pathways Taken by Receptor Tyrosine Kinase
Figure 5-2: Steps Involved in PI3K/Akt Pathway
Figure 5-3: Signaling Pathway Followed by Ras/Raf/ERK1/2 Pathway
Figure 5-4: Signaling Pathway of JAK STAT Tyrosine Kinase Receptors
Figure 10-1: Applications of Tyrosine Kinase Inhibitors in Cancer Therapy
Figure 11-1: Global Cancer Kinase Inhibitors Market Opportunity (US$ Billion), 2015-2020
Figure 11-2: Global Cancer Tyrosine Kinase Inhibitors Clinical Pipeline by Phase (%), 2016
Figure 11-3: Global Cancer Tyrosine Kinase Inhibitors Clinical Pipeline by Phase (Numbers), 2016
Figure 11-4: Global Cancer Tyrosine Kinase Inhibitors Clinical Pipeline by Phase (%), 2016
Figure 11-5: Global Cancer Tyrosine Kinase Inhibitors Clinical Pipeline by Phase (Numbers), 2016
Figure 12-1: Various Driving Factors Involved in Establishment of Tyrosine Kinase Inhibitor Market
Figure 12-2: List of the Drugs In Different Phases of Clinical Trials
Figure 12-3: List of Main Challenges Which Hamper Development of Tyrosine Kinase Inhibitors
Figure 17-1: AB Scicence - Clinical Pipeline
Figure 17-2: Advenchen Laboratories - Clinical Pipeline
Figure 17-3: ARIAD - Clinical Pipeline
Figure 17-4: Biocon - linical Pipeline
Figure 17-5: Celgene Corporation - Clinical Pipeline
Figure 17-6: Daiichi Sankyo - Clinical Pipeline
Figure 17-7: Novartis - Clinical Pipeline
Figure 17-8: Plexxikon - Clinical Pipeline
Figure 17-9: Roche - Clinical Pipeline
Figure 17-10: Zydus Cadila - Clinical Pipeline

Table 3-1: Recently Approved Tyrosine Kinase Inhibitors
Table 4-1: ErbB Family Members & Their Ligands
Table 4-2: Platelet-Derived Growth Factor Receptor & Ligands
Table 4-3: Receptor Platelet Derived Tyrosine Kinase & the Cancers Associated
Table 4-4: Insulin Receptor Family Members & Its Ligands
Table 7-1: List of Tyrosine Kinase Inhibitors Developed against BCR-ABL Receptors
Table 8-1: List of the Drugs Targeting EFGR Receptor
Table 9-1: Different Drugs associated with The Treatment of Angiogenesis Related Cancers
Table 10-1: Tyrosine Kinase Inhibitors Targeting Lung Cancer
Table 10-2: Drugs being Developed to Treat Hematological Malignancies
Table 10-3: Drugs Used to Manage Breast Cancer
Table 10-4: Some of the Tyrosine Kinase Inhibitors Developed to Treat Metastatic Melanoma
Table 11-1: Drugs to Enter the Market in Near Future

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.